PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 51 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $10,000 | -71.4% | 58,119 | 0.0% | 0.00% | – |
| Q2 2022 | $35,000 | -54.5% | 58,119 | 0.0% | 0.00% | – |
| Q1 2022 | $77,000 | -53.0% | 58,119 | -7.3% | 0.00% | – |
| Q4 2021 | $164,000 | -15.9% | 62,706 | 0.0% | 0.00% | – |
| Q3 2021 | $195,000 | -18.8% | 62,706 | -2.8% | 0.00% | – |
| Q2 2021 | $240,000 | -58.5% | 64,481 | -61.4% | 0.00% | – |
| Q1 2021 | $579,000 | +4.1% | 167,264 | +1.2% | 0.00% | – |
| Q4 2020 | $556,000 | -5.1% | 165,340 | -1.0% | 0.00% | – |
| Q3 2020 | $586,000 | -23.5% | 166,939 | +0.2% | 0.00% | – |
| Q2 2020 | $766,000 | +35.3% | 166,623 | -2.6% | 0.00% | – |
| Q1 2020 | $566,000 | -34.9% | 171,081 | +20.1% | 0.00% | – |
| Q4 2019 | $870,000 | +34.3% | 142,393 | -8.4% | 0.00% | – |
| Q3 2019 | $648,000 | +33.3% | 155,420 | +319.7% | 0.00% | – |
| Q2 2019 | $486,000 | – | 37,027 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |